Human Serum amyloid A protein Reference standard
Cat.No. : | amyloid A-123H |
Product Overview : | Calibrant for serum amyloid A assays. |
- Specification
- Gene Information
- Related Products
Species : | Human |
Enzyme Unit : | 0.15 International Units (IU) per ampoule. |
Usage : | No attempt should be made to weigh out any portion of the material. For all practical purposes each ampoule contains the same amount of the same materials. Dissolve the total contents in a known amount of distilled water and make further dilutions in a suitable buffer solution with carrier protein (free of peptidase), where extensive dilution is required, to minimise loss by surface adsorption. No attempt should be made to weigh out any portion of the freeze-dried powder. For economy of use it is recommended that the solution be subdivided into several small containers, which are frozen rapidly to below –40°C and then stored below –40°C in the dark. Repeated freeze thawing should be avoided. Suitable precautions should be taken in the use and disposal of the ampoule and its contents. |
Notes : | This preparation is not for administration to humans. This preparation contains material of human origin. It has been tested and found negative for HBsAg and anti-HIV. The preparation gave a positive antibody test and a positive PCR test for HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratorys safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts. |
Stability : | They remain valid with the assigned potency and status until withdrawn or amended. Reference materials are held at Creative Biomart within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label. In addition, once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact Creative Biomart. |
Storage : | Unopened ampoules should be stored at –20°C. Please note: because of the inherent stability of lyophilized material, Creative Biomart may ship these materials at ambient temperature. |
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (18)
Ask a questionYes, there are support groups and resources available for individuals and families affected by amyloid A protein-related diseases. These organizations provide information, support, and a community where individuals can connect with others facing similar challenges. Examples of such organizations include the Amyloidosis Foundation and the Amyloidosis Support Groups.
Prevention strategies for amyloid A protein-related diseases primarily involve managing the underlying conditions, such as chronic inflammation or infection. This may include lifestyle modifications, such as adopting a healthy diet, maintaining a healthy weight, and effectively managing chronic inflammatory conditions or infections through appropriate medical care.
Various research studies are focused on identifying strategies to target amyloid A protein and reduce its deposition in tissues. This includes the development of anti-amyloid agents or drugs that can inhibit amyloid A fibril formation or promote their clearance. However, such interventions are still under investigation and not widely available.
In chronic inflammatory conditions, the deposition of amyloid A protein in blood vessels can lead to inflammation and damage to the vessel walls. This can contribute to the development of cardiovascular diseases, including atherosclerosis and coronary artery disease.
Amyloid A protein and amyloid beta protein are different proteins associated with different diseases. Amyloid A protein is involved in amyloidosis, specifically AA amyloidosis, which is associated with chronic inflammation. On the other hand, amyloid beta protein is associated with Alzheimer's disease and forms the plaques found in the brains of affected individuals.
Yes, there are ongoing clinical trials exploring potential therapies for amyloid A protein-related diseases, including new treatments to reduce amyloid A protein formation or promote its clearance. These trials aim to provide better management options for individuals with amyloid A protein-related diseases.
In amyloidosis, amyloid A protein becomes misfolded and aggregates into insoluble fibrils. These fibrils can deposit in different organs, leading to tissue damage and dysfunction. The exact mechanism by which amyloid A protein undergoes misfolding and aggregation is still not fully understood.
The treatment for amyloid A protein-related diseases primarily focuses on managing the underlying condition causing the deposition of amyloid A protein. This may involve treating the chronic inflammation or infection, if present. In some cases, medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or disease-modifying antirheumatic drugs (DMARDs) may be used to reduce inflammation and control symptoms.
Amyloid A protein deposition is seen in various diseases, collectively known as amyloidosis. This includes primary amyloidosis (AL amyloidosis), which affects multiple organs, and secondary amyloidosis (AA amyloidosis), which is associated with chronic inflammatory conditions such as rheumatoid arthritis or chronic infections.
Certain lifestyle factors, such as diet and obesity, may influence amyloid A protein levels. For example, a high-fat diet and obesity can lead to increased amyloid A protein production. However, more research is needed to fully understand the impact of lifestyle factors on amyloid A protein and its associated diseases.
Amyloid A protein can be cleared from the body with appropriate treatment. For example, targeting the underlying condition causing amyloidosis can lead to a reduction in amyloid A protein levels over time. In some cases, organ transplantation, such as liver transplantation, may be considered to replace the source of amyloid A protein production.
Management of amyloidosis associated with amyloid A protein involves treating the underlying chronic inflammatory condition. In some cases, medications called anti-inflammatory drugs or biologic agents may be prescribed to control inflammation and reduce amyloid A protein production. In severe cases, organ-specific treatments like liver or stem cell transplant may be considered.
Yes, researchers are actively studying various approaches to target amyloid A protein as a potential therapy. This includes developing drugs that can inhibit the production of amyloid A protein, promote its clearance from tissues, or prevent its deposition and aggregation. These approaches hold promise for the future treatment of amyloid A protein-related diseases.
Yes, amyloid A protein can be measured in the blood using laboratory tests. High levels of amyloid A protein indicate an inflammatory response and can serve as a marker for monitoring disease activity in certain conditions.
At present, there is no known cure for amyloid A protein-related diseases. Treatment primarily focuses on managing the underlying conditions and reducing symptoms. Research efforts continue to uncover new therapeutic approaches that may offer better management or potential cure in the future.
Yes, mutations in genes such as the SAA1 and SAA2 genes, which encode amyloid A protein, can increase the risk of developing amyloidosis. However, these mutations are rare and not commonly seen in individuals with amyloid A protein diseases.
Yes, amyloid A protein levels in the blood can be measured to assess disease activity and response to treatment in certain inflammatory conditions. However, it is important to note that amyloid A protein measurement alone is not sufficient for diagnosing amyloidosis, and additional tests, such as tissue biopsy, are often required.
Yes, amyloid A protein can also deposit in other tissues, including joints, skin, and the gastrointestinal tract. The specific deposition pattern may vary depending on the underlying condition causing amyloidosis.
Customer Reviews (5)
Write a reviewThe manufacturer plays a crucial role in supporting my research with their extensive expertise and resources.
By using amyloid A protein, I can gain insights into the underlying molecular processes contributing to amyloidosis, which can ultimately aid in the development of novel therapeutic strategies.
This assurance enables me to confidently utilize the amyloid A protein in my research, knowing that it will consistently deliver reliable and accurate results.
the manufacturer facilitates access to the latest scientific advancements and developments related to amyloid A protein research.
the amyloid A protein is an exceptional tool for investigating the intricate mechanisms and pathogenesis of amyloid-related diseases.
Ask a Question for All amyloid A Products
Required fields are marked with *
My Review for All amyloid A Products
Required fields are marked with *
Inquiry Basket